CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Service Receivable	Accumulated Deficit
Balance, beginning (in shares) at Dec. 31, 2018		60,600	3,831,879
Balance, beginning at Dec. 31, 2018	$ 10,084,192	$ 60	$ 7,742	$ 202,267,605	$ 0	$ (192,191,215)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	200,067			200,067
Issuance of common stock upon exercise of warrants (in shares)			497,313
Issuance of common stock upon exercise of warrants	3,282,266		$ 50	3,282,216
Issuance of common stock upon vesting of restricted stock units (in shares)			6,362
Issuance of common stock upon vesting of restricted stock units			$ 4	(4)
Preferred stock dividend payable on Series A Convertible Preferred Stock	(6,060)					(6,060)
Net loss	(3,904,771)					(3,904,771)
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses of $40,000 (in shares)		200,000	183,334
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount of $40,000 and $235,640, respectively	(40,000)	$ 200	$ 110	1,634,690	(1,675,000)
Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance				268,269		(268,269)
Issuance of common stock for share rounding as a result of reverse stock split (in shares)			6,466
Release of clinical trial funding commitment	70,487				70,487
Balance, ending (in shares) at Mar. 31, 2019		260,600	4,525,354
Balance, ending at Mar. 31, 2019	9,686,181	$ 260	$ 7,906	207,652,843	(1,604,513)	(196,370,315)
Balance, beginning (in shares) at Dec. 31, 2019		60,600	8,593,633
Balance, beginning at Dec. 31, 2019	7,311,344	$ 60	$ 8,312	217,172,528	(971,673)	(208,897,883)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	177,309			177,309
Sale of common stock and warrants (in shares)			(800,000)
Sale of common stock and warrants	(1,000,001)		$ (80)	(999,921)
Issuance of common stock upon exercise of warrants (in shares)			1,610,144
Issuance of common stock upon exercise of warrants	1,456,369		$ 161	1,456,208
Issuance of common stock upon vesting of restricted stock units (in shares)			6,810
Issuance of common stock upon vesting of restricted stock units			$ 1	(1)
Preferred stock dividend payable on Series A Convertible Preferred Stock	(6,060)					(6,060)
Net loss	(4,088,562)					(4,088,562)
Release of clinical trial funding commitment	293,017				293,017
Balance, ending (in shares) at Mar. 31, 2020		60,600	11,010,587
Balance, ending at Mar. 31, 2020	$ 6,143,418	$ 60	$ 8,554	$ 219,805,965	$ (678,656)	$ (212,992,505)